Related Experiment Video
Updated: Jun 4, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Helicobacter pylori Infection and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Study and
Longgang Zhao1, Yun Chen1, Xinyuan Zhang2
1Yale University School of Nursing, Orange, Connecticut.
Background:
Helicobacter pylori infection and metabolic dysfunction-associated steatotic liver disease (MASLD) are significant global health concerns, but their association remains unclear, with evidence mainly from cross-sectional studies and Asian populations.
Methods:
We analyzed UK Biobank (UKB) participants ages 40 to 69 years with objectively measured H. pylori serostatus data (N = 4,246). Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI), adjusting for demographic, lifestyle, and cardiometabolic factors. We meta-analyzed seven prospective cohorts (all from non-European populations) and the UKB (8 cohorts in total with 36,145 participants and 6,979 cases) to evaluate the association between H. pylori seropositivity and MASLD risk.
Results:
About 35.1% of the participants were seropositive for H. pylori in the UKB. With a median follow-up of 11.1 years, we identified 32 MASLD cases. H. pylori seropositivity was marginally associated with higher MASLD risk (HR, 1.88; 95% CI, 0.92-3.82), whereas cytotoxin-associated gene A (CagA) seropositivity was significantly associated with higher risk (2.40; 1.17-4.92). Participants seropositive for both H. pylori and CagA had a higher MASLD risk than participants seronegative for both markers (2.58; 1.19-5.61). The meta-analysis showed that H. pylori was associated with a 24% higher MASLD risk (risk ratio, 1.24; 95% CI, 1.17-1.31).
Conclusions:
H. pylori infection, particularly CagA seropositivity, was associated with higher MASLD risk in prospective studies.
Impact:
Our findings support a potential role of H. pylori virulence serology (CagA) in MASLD development. If confirmed, these findings could have implications for risk stratification and inform targeted eradication or prevention strategies.
Related Concept Videos
Gastritis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Pathophysiology
Cirrhosis II: Pathophysiology
Cholecystitis
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

